[Comparative pharmacokinetic study between UFT and FT-207 suppo and phase II studies in gynecological malignancies].
Plasma pharmacokinetics and accumulation into tissues were comparatively examined between UFT and FT-207 suppo and 7 gynecological malignancies were treated by UFT in a phase-II study. FT-207 suppo, the maximum level was attained. After administration, UFT plasma FT reached its maximum level at 2-3 hr, but for 0.5-1 hr after administration. On the other hand, plasma 5-FU concentration reached its peak 1-2 hr or 3-4 hr after UFT administration and revealed very low levels after FT-207 suppo administration. 5-FU accumulation in normal tissue (NT) was not proportional to administered doses of UFT, but in cancerous tissue (CT) it was dependent on total UFT dose. The CT/NT ratio with respect to 5-FU concentration was 5.36 after UFT administration. The same ratio after FT-207 suppo administration was 2.63. The specificity of 5-FU accumulation into cancerous tissue after UFT administration was significantly demonstrated. According to the Evaluating Criteria for cancer chemotherapy in solid tumors by the Japanese Society for Cancer Therapy, we obtained results of PR 2, NC 2 and PD 3 using a 600 mg/day administration of UFT for 7 gynecological malignancies consisting of 6 cervical carcinomas and 1 endometrial carcinoma.
D000368:Aged; D000970:Antineoplastic Agents / Q000378:metabolism* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000097:blood; D006801:Humans; D007700:Kinetics; D008875:Middle Aged; D005641:Tegafur / Q000378:metabolism* / Q000627:therapeutic use; D014498:Uracil / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D000970:Antineoplastic Agents; D005641:Tegafur; D014498:Uracil; D005472:Fluorouracil